Arcutis Biotherapeutics, Inc. ARQT

ARQT Company Overview

Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-dermatologic diseases. The company operates within the biotechnology and specialty pharmaceuticals industries, with a strategic emphasis on inflammatory skin conditions that have significant unmet medical need. Its business model centers on the discovery, clinical development, regulatory approval, and commercialization of targeted topical therapies.

Arcutis’ primary revenue driver is ZORYVE® (roflumilast), a non-steroidal, topical phosphodiesterase-4 (PDE4) inhibitor approved in multiple formulations for chronic inflammatory dermatologic conditions. The company targets both dermatologists and patients seeking alternatives to topical steroids. Founded in 2016, Arcutis evolved from a development-stage company into a commercial organization following U.S. Food and Drug Administration approvals beginning in 2022, establishing its presence in the U.S. dermatology market.